SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001618835-23-000015
Filing Date
2023-03-10
Accepted
2023-03-10 17:27:45
Documents
12
Period of Report
2023-03-07
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K evfm-20230307.htm   iXBRL 8-K 38262
  Complete submission text file 0001618835-23-000015.txt   174461

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20230307.xsd EX-101.SCH 1896
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20230307_lab.xml EX-101.LAB 23892
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20230307_pre.xml EX-101.PRE 12519
6 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20230307_htm.xml XML 10798
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 23724970
SIC: 2834 Pharmaceutical Preparations